- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04248582
Cryotherapy for Locally Advanced Esophageal Cancer
Phase 1 Dose-Frequency Escalation Study of Neoadjuvant Cryotherapy in Locally Advanced Esophageal Cancer
Background: In published studies, complete response (CR) to chemoradiation occurs in only 25-30% of patients with locally advanced esophageal cancer. Liquid nitrogen spray cryotherapy (LNSC) is postulated to stimulate an anti-tumor immune response. In a preliminary study, the investigators documented CR rate of 56% with a single session of LNSC administered prior to chemoradiation. Before proceeding with larger trials to corroborate these findings, the maximally tolerated dose (MTD) of neoadjuvant LNSC must be determined. The aims of this study are: (1) To determine safety and MTD of LNSC during neoadjuvant chemoradiation in locally advanced esophageal cancer. (2) To assess whether LNSC results in immunogenic cell death. (3) To assess changes in tumor micro-environment with LNSC.
Methods: Eligible adult patients with locally advanced esophageal cancer will receive LNSC at the following dose frequencies: Patient 1, 2, and 3: 2 sessions of LNSC prior to chemoradiation (chemoXRT); Patients 4, 5, and 6: 2 sessions LNSC prior to chemoXRT, then 1 session during week 4 of chemoXRT; Patients 7, 8, and 9: 2 sessions LNSC prior to chemoXRT, then 1 session during week 2 and 1 session during week 4 of chemoXRT. If no dose limiting toxicity (DLT) occurs, the investigators will enroll an additional 3 patients to confirm MTD. The investigators will contact patients at 48-hours and 1-week post-procedure to evaluate for adverse events (AEs) and DLTs, and assess for improvements in dysphagia and quality of life (QOL) using the Mellow-Pinkas and EORTC QLQ-OES18 instruments respectively. The investigators will obtain peripheral blood for ELISA and biopsies from the tumor to assess tumor-infiltrating lymphocytes (TILs) and T cell subtypes before the 1st session of LNSC, before the 2nd session of LNSC, and after chemoradiation is completed.
Expected results: (1) Dose limiting toxicity (DLT) does not occur when patients received 2 session of LNSC prior to chemoXRT, and 2 sessions during chemoXRT (2) LNSC results in immunogenic cell death, as assessed by increased levels of HMGB1 in serum, and calreticulin in biopsy specimens (CRT) (3) LNSC is associated with increased T cell infiltration and activation (increased TILs, CD8+, CD3+ T cells, and granzyme B), and decrease in regulatory T cells (CD45R0, FOXP3).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
LNSC will be administered as follows: up to three cycles of 20 to 40 seconds each directed at the bulkiest aspect of the tumor. During each cycle, a surface area of approximately 2 to 3 cm2 is targeted. Up to three sites are treated during each session. Tissue thawing is verified between cycles by waiting at least 60 seconds before re-treatment, and by observing a return to baseline color of the tissue and complete disappearance of ice crystals after reperfusion. After the procedure is completed, patients will be monitored in the recovery unit for at least 30 minutes. Patients will be discharged after monitoring if they meet the endoscopy unit's standard discharge criteria.
Cryotherapy dose frequency intervals
- Two LNSC sessions (patient 1, 2, and 3): 2 sessions of LNSC administered at 2-week intervals, followed by concurrent chemoradiation for 5 weeks.
- Three LNSC sessions (patients 4, 5, and 6): 2 sessions of LNSC administered at 2-week intervals, followed by concurrent chemoradiation for 5 weeks. During week 4 of chemoradiation, they will receive a session of LNSC.
Four LNSC sessions (patients 7, 8, and 9): 2 sessions of LNSC administered at 2-week intervals, followed by concurrent chemoradiation for 5 weeks. During week 2 and week 4 of chemoradiation, they will receive LNSC (i.e. - 2 sessions during chemoradiation).
- No DLTs: If no patient develops a DLT, then the investigators will enroll an additional 3 patients to receive 4 LNSC sessions as described earlier, in order to confirm safety.
- 1 DLT: If 1 of 3 patients develops a DLT, then the investigators will enroll 3 additional patients to receive LNSC at that dose. If any of the additionally enrolled patients develop a DLT, the investigators will enroll 3 patients at the previous dose, to confirm safety of the lower dose frequency.
- 2 DLTs: At a given dose frequency interval, if 2 of 3 patients develop a DLT, then the investigators will enroll 3 patients at the previous dose, to confirm safety of the lower dose frequency.
Definition of Adverse Events (AEs) and Dose Limiting Toxicity (DLT) We will define adverse AEs based on the American Society of Gastrointestinal Endoscopy (ASGE) lexicon (Appendix 2). The relationship of the AE to LNSC will be classified using the following 4 categories: definitely related, likely related, unlikely related, and definitely not related. DLT will be defined as any severe or fatal adverse event that is definitely or likely related to the cryotherapy procedure (i.e. - unplanned admission > 10 nights, intensive care unit admission > 1 night, surgery for an adverse event, permanent disability due to an adverse event, or death). A member of the study team will contact patients and review their medical records 48 hours after the procedure, and 1 week after the procedure to assess for mild, moderate, and severe adverse events (AEs). In addition to recording any AEs, the study coordinator will contact a physician investigator if any AEs are reported in order to direct appropriate clinical management. An independent data safety monitoring (DSM) committee will review AEs every 3 months for the duration of the study to determine whether the AE was definitely or likely related to the LNSC procedure. Additionally, if a serious adverse event (SAE) is reported, then the DSM will meet within one week to determine if the SAE represents a DLT.
Tissue morphology, flow cytometry, and immunohistochemistry (IHC) The investigators will obtain peripheral blood and 6 mucosal biopsies (2 mm X 2 mm) immediately prior to the first and second session of cryotherapy, and at the end of chemoradiation. The investigators will obtain half the biopsies from the center, and half the biopsies from the periphery of the tumor. If the patient proceeds directly to surgery following chemoradiation without endoscopy, then the investigators will obtain archival tissue from the explant specimen. The investigators will place 2 biopsies in 4% paraformaldehyde (PFA) for TILs analysis (1 center and 1 periphery), 2 biopsies in 4% PFA for IHC analysis (1 center and 1 periphery), and 2 biopsies for exploratory analyses/backup. To assess for evidence of immunogenic cell death, the investigators will perform IHC on biopsy specimens for CRT, and ELISA on peripheral blood for HMBG1. A pathologist blinded to patient demographics, and treatment allocation will grade overall inflammation using standard criteria and as sparse, moderate, or pronounced TILs. To assess the immune infiltrate, the investigators will construct tissue microarray (TMA) blocks and analyze in an automated immunostainer for antibodies against the following antigens: CD3, CD8, CD45R0/FoxP3, and Pan-CK.
Other Data Collection Baseline variables: Baseline variables will include age, gender, ethnicity, tumor histology and TNM stage, location and length of tumor, presence or absence of critical organ invasion (i.e. - aorta, trachea, heart, and vertebral body), ECOG performance status, baseline Mellow-Pinkas dysphagia score, and a validated measure of quality of life in esophageal cancer, the EORTC QLQ-OES18.
Assessment of pathologic/clinical complete response: At the completion of neo-adjuvant chemoradiation, results of the re-staging PET-CT and surgical explant will be abstracted to document presence or absence of a pathologic complete response. As is standard protocol at our institutions, patients who do not undergo surgery will undergo upper endoscopy with biopsies along with PET-CT to assess for the presence or absence of a clinical complete response.
Assessment of palliation efficacy: A member of the study team will contact each patient at 1-week after each LNSC procedure to update the Mellow-Pinkas dysphagia score and EORTC QLQ-OES18. The investigators will also document if there was any need for an esophageal stent, enteral feeding tube, or parenteral nutrition support during chemoradiation.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Shelkieta R Kelley
- Phone Number: 804-675-5677
- Email: Shelkieta.Kelley@va.gov
Study Contact Backup
- Name: Angela Davis
- Phone Number: 804.675.5676
- Email: Angela.Davis@va.gov
Study Locations
-
-
Virginia
-
Richmond, Virginia, United States, 23249
- Hunter Holmes McGuire VA Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Adult patients with locally advanced esophageal cancer will be eligible to participate in the study. Eligible patients must have a histologically proven diagnosis of esophageal adenocarcinoma, esophageal squamous cell carcinoma, adenosquamous carcinoma, or gastro-esophageal junctional adenocarcinoma. Locally advanced esophageal cancer will be defined as absence of distant metastases on positron emission tomography-computed tomography (PET-CT) and a TNM stage of IIA to IIIC, as defined by endoscopic ultrasound and PET-CT
Exclusion Criteria:
- Pediatric patients (age less than 18 years)
- Superficial esophageal cancer
- Inability to pass the orogastric decompression tube into the stomach
- Coagulopathy (INR > 2 or platelet count < 50,000/cubic millimeter).
- Inability to provide informed consent
- Eastern Cooperative Oncology Group (ECOG) performance status ≥3
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cryotherapy before chemoradiation
Patients receive 2 sessions of liquid nitrogen spray cryotherapy prior to chemoradiation
|
LNSC will be performed with low-pressure liquid nitrogen (<5 psi) at 25 watts using a cryotherapy catheter passed through the working channel of the endoscope.We will plan to administer LNSC as follows: up to three cycles of 20 to 40 seconds each directed at the bulkiest aspect of the tumor.
During each cycle, a surface area of approximately 2 to 3 cm2 is targeted.
Up to three sites are treated during each session.
Tissue thawing is verified between cycles by waiting at least 60 seconds before re-treatment, and by observing a return to baseline color of the tissue and complete disappearance of ice crystals after reperfusion.
After the procedure is completed, patients will be monitored in the recovery unit for at least 30 minutes.
Patients will be discharged after monitoring if they meet the endoscopy unit's standard discharge criteria.
Other Names:
|
Experimental: Cryotherapy before chemoradiation and during
Patients receive 2 sessions of liquid nitrogen spray cryotherapy prior to chemoradiation and one session during chemoradiation
|
LNSC will be performed with low-pressure liquid nitrogen (<5 psi) at 25 watts using a cryotherapy catheter passed through the working channel of the endoscope.We will plan to administer LNSC as follows: up to three cycles of 20 to 40 seconds each directed at the bulkiest aspect of the tumor.
During each cycle, a surface area of approximately 2 to 3 cm2 is targeted.
Up to three sites are treated during each session.
Tissue thawing is verified between cycles by waiting at least 60 seconds before re-treatment, and by observing a return to baseline color of the tissue and complete disappearance of ice crystals after reperfusion.
After the procedure is completed, patients will be monitored in the recovery unit for at least 30 minutes.
Patients will be discharged after monitoring if they meet the endoscopy unit's standard discharge criteria.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose limiting toxicity (DLT)
Time Frame: 12 weeks
|
We hypothesize that 1) DLT will not occur when patients receive 2 sessions of LNSC prior to chemoradiation, and 2 sessions during chemoradiation (i.e. - a total of 4 sessions) for locally advanced esophageal cancer
|
12 weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Tilak Shah, MD, McGuire VA Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SHAH 008
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Esophageal Cancer
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityWithdrawnStage IIB Esophageal Cancer AJCC v7 | Stage III Esophageal Cancer AJCC v7 | Stage IIIA Esophageal Cancer AJCC v7 | Stage IIIB Esophageal Cancer AJCC v7 | Stage IIIC Esophageal Cancer AJCC v7
-
National Cancer Institute (NCI)NRG OncologyCompletedEsophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Stage IIA Esophageal Cancer AJCC v7 | Stage IIB Esophageal Cancer AJCC v7 | Stage IIIA Esophageal Cancer AJCC v7 | Stage IIIB Esophageal Cancer AJCC v7 | Stage IB Esophageal Cancer AJCC v7United States
-
AIO-Studien-gGmbHBristol-Myers SquibbCompletedEsophageal Cancer | Gastrooesophageal Cancer | Oesophageal Cancer | GastroEsophageal Cancer | Esophageal Cancers NOS | Oesophageal Cancer Metastatic | Esophageal Cancer Metastatic | Oesophageal Cancer NosGermany
-
Cancer Institute and Hospital, Chinese Academy...Tianjin Medical University Cancer Institute and Hospital; Sichuan Cancer Hospital...UnknownEsophageal Neoplasm | Esophageal Cancer TNM Staging Primary Tumor (T) T3 | Esophageal Cancer TNM Staging Primary Tumor (T) T2 | Esophageal Cancer TNM Staging Regional Lymph Nodes (N) N0 | Esophageal Cancer TNM Staging Distal Metastasis (M) M0China
-
University of Wisconsin, MadisonActive, not recruitingResectable Esophageal Cancer | GastroEsophageal CancerUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...UMC UtrechtCompletedEsophageal Cancer, Stage II | Esophageal Cancer Stage IIINetherlands
-
Tianjin Medical University Cancer Institute and...The First Affiliated Hospital with Nanjing Medical University; The First Affiliated... and other collaboratorsUnknownEsophageal Cancer Stage III | Esophageal Cancer Stage IIBChina
-
Tianjin Medical University Cancer Institute and...Sun Yat-sen University; Cancer Institute and Hospital, Chinese Academy of Medical... and other collaboratorsNot yet recruitingStage III Esophageal Cancer | Stage II Esophageal Cancer
-
Tianjin Medical University Cancer Institute and...UnknownStage III Esophageal Cancer | Stage II Esophageal CancerChina
-
National Cancer Institute (NCI)RecruitingNeoplasms | Esophageal Neoplasms | Esophagus Cancer | Esophagus Neoplasm | Neoplasms, Esophageal | Esophageal Cancer (EsC)United States
Clinical Trials on Cryotherapy
-
Cairo UniversityNot yet recruiting
-
Creighton UniversityCompleted
-
Hanyang University Seoul HospitalCompletedCryotherapy EffectKorea, Republic of
-
Ondokuz Mayıs UniversityRecruitingPain, Postoperative | Pulpitis | Caries; DentinTurkey
-
Entellus Medical, Inc.North American Science Associates Inc.Active, not recruiting
-
CSA Medical, Inc.WithdrawnLung Diseases, Obstructive | Airway Obstruction | Lung Disease Airways | Airway; Obstruction, With Emphysema
-
Unity Health TorontoRecruitingRetinal Detachment | MetamorphopsiaCanada
-
Flávia CarvalhoNot yet recruitingFunctional Status | Muscle Tone
-
Sohag UniversityMansoura UniversityNot yet recruitingObstructive Sleep Apnea Syndrome
-
H. Lee Moffitt Cancer Center and Research InstituteColumbia University; University Hospitals Cleveland Medical Center; Geisinger... and other collaboratorsSuspendedBleeding | GAVE - Gastric Antral Vascular Ectasia | Bleeding GastricUnited States